Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial

BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder of unknown etiology with systemic symptoms that include fever, night sweats, weight loss, and fatigue. Although tocilizumab (TCZ), which is a recombinant, humanized, anti-human interleukin 6 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Tomohiro, Hagimori, Naoko, Takemori, Sachiko, Morimoto, Shimpei, Sumiyoshi, Remi, Shimizu, Toshimasa, Hosogaya, Naoki, Fukushima, Chizu, Yamamoto, Hiroshi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387047/
https://www.ncbi.nlm.nih.gov/pubmed/32791665
http://dx.doi.org/10.1097/MD.0000000000020710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387047/
https://www.ncbi.nlm.nih.gov/pubmed/32791665
http://dx.doi.org/10.1097/MD.0000000000020710

Ejemplares similares